ZYME Earnings Date: Nov 9, 2026 (Estimated) — Zymeworks Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ZYME's next earnings date?
Zymeworks Inc. (ZYME) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.27 on revenue of $227.4M.
How did ZYME do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Zymeworks Inc. posted EPS of -$0.62 versus the -$0.57 estimate, a miss of 55.0%. Revenue was $4.6M against a $4.5M estimate. The stock's 1-day post-earnings move was +1.8%.
How much does ZYME stock move after earnings?
ZYME beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.1% (up or down) in the day after earnings.
About Zymeworks Inc.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.57 | -0.62 | -55.00% | $4.6M | ❌ Miss | +1.77% | +11.37% | +26.20% |
| 2026-05-07 | Q1 2026 | -0.10 | -0.59 | -490.00% | $2.4M | ❌ Miss | -10.19% | -9.92% | -10.04% |
| 2026-03-02 | Q4 2025 | -0.33 | -0.55 | -66.67% | $2.5M | ❌ Miss | +0.09% | +3.39% | +3.95% |
| 2025-11-06 | Q3 2025 | -0.31 | -0.26 | +16.13% | $27.6M | ✅ Beat | -8.04% | +3.35% | +47.54% |
| 2025-08-07 | Q2 2025 | -0.48 | 0.03 | +106.25% | $48.7M | ✅ Beat | -1.15% | +17.60% | +24.92% |
| 2025-05-08 | Q1 2025 | -0.45 | -0.30 | +33.33% | $27.1M | ✅ Beat | -0.13% | +1.86% | +9.98% |
| 2025-03-05 | Q4 2024 | -0.09 | -0.31 | -244.44% | $31.0M | ❌ Miss | -7.97% | -6.83% | -10.85% |
| 2024-10-31 | Q3 2024 | -0.40 | -0.39 | +2.50% | $16.0M | ✅ Beat | -3.07% | +22.41% | +5.84% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Royalty | 84.5% | $1.6M | +188.9% | — | $202K | $550K | $831K |
| Research Support Payments And Other Service | 15.5% | $291K | -38.7% | — | $4.5M | $475K | $352K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.